Treatment of Axial Spondyloarthritis: What Does the Future Hold?

AbstractPurpose of ReviewTo provide a summary of the recent and expected developments related to the treatment of axial spondyloarthritis.Recent FindingsAn increasing number of interleukin-17 blocking agents show efficacy in axial spondyloarthritis including both non-radiographic and radiographic forms. Janus kinase inhibitors showed promising results in phase II studies in radiographic axial spondyloarthritis and have, therefore, a potential to become a therapeutic option in this indication in the future. Inhibition of structural damage progression in axial spondyloarthritis seems to be possible in the case of effective and early anti-inflammatory treatment, although there are still open questions related to particular drug classes.SummaryDespite major advances in the field and growing therapeutic options, there are still many open questions related to the optimized treatment strategies and to the individual choice of a drug in axial spondyloarthritis.
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research